Darmstadt (Free subscription) | 11/16/2009
... joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA ...
Medical News Today (Free subscription) | 11/20/2009
Genzyme Corporation (Nasdaq: GENZ) reported results of a phase 2/3 study of its advanced phosphate binder (APB). The trial met its primary endpoint, which was to show that the APB lowered phosphate levels effectively compared to placebo. However, the APB did not show a significant improvement in phosphate lowering compared to Genzyme's Renvela® (sevelamer carbonate). Based...
Business Wire (Free subscription) | 11/18/2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) today reported results of a phase 2/3 study of its advanced phosphate binder (APB). The trial met its primary endpoint, which was to show that the APB lowered phosphate levels effectively compared to placebo. However, the APB did not show a significant improvement in phosphate lowering compared to Genzyme’s...
Business Wire (Free subscription) | 11/16/2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) announced today that it has received a complete response letter from the FDA regarding its application to market Lumizyme™ (alglucosidase alfa) for the treatment of Pompe disease. In its letter, the agency stated that satisfactory resolution of deficiencies related to the Allston Landing manufacturing plant are...
PR News Wire (Free subscription) | 11/11/2009
CARLSBAD, Calif., Nov. 11 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Genzyme Corporation (Nasdaq: GENZ) announce the following webcast:
NewsInferno (Free subscription) | 11/16/2009
The U.S. Food and Drug Administration and Genzyme Corporation are advising endocrinological and genetics medicine healthcare professionals that Genzyme products marketed as Cerezyme, Fabrayzme, Myozyme, Aldurazyme, and Thyrogen are potentially tainted with foreign particles. The medications are used to treat rare, serious, and life-threatening diseases. The foreign particles include...
Red Orbit (Free subscription) | 11/13/2009
NOVATO, Calif., Nov. 13 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Genzyme notified the company that, in rare circumstances, it has detected foreign particles in some products filled at the Allston Landing facility.
Red Orbit (Free subscription) | 11/11/2009
CARLSBAD, Calif., Nov. 11 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc.
Business Wire (Free subscription) | 10/23/2009
CHICAGO--(BUSINESS WIRE)--Zacks.com releases details on a group of stocks that are currently members of the exclusive Zacks #5 Rank List – Stocks to Sell Now. These stocks are currently rated as a Zacks Rank #5 (Strong Sell): Pinnacle Financial Partners (Nasdaq: PNFP) and Marten Transport Ltd. (Nasdaq: MRTN). Further, Zacks announced #4 Rankings (Sell) on two other widely held stocks: Genzyme...
SeekingAlpha.com (Free subscription) | 10/22/2009
Genzyme Corporation ( GENZ ) Q3 2009 Earnings Call Transcript October 21, 2009 11:00 am ET Complete Story »
Business Wire (Free subscription) | 10/20/2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (NASDAQ: GENZ) today announced that the company has begun enrollment in the first of two global, multi-center, phase 3 trials of Genz-112638, a potential new oral therapy for Gaucher disease type 1. The two multi-national, multi-center trials are being conducted to evaluate the safety and efficacy of the small molecule. The first...
Medical News Today (Free subscription) | 10/22/2009
Genzyme Corporation (NASDAQ: GENZ) announced that the company has begun enrollment in the first of two global, multi-center, phase 3 trials of Genz-112638, a potential new oral therapy for Gaucher disease type 1. The two multi-national, multi-center trials are being conducted to evaluate the safety and efficacy of the small molecule.
Business Wire (Free subscription) | 10/14/2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) announced today that scientists have again named the company a top employer in a survey ranking the reputations of biotechnology and pharmaceutical companies. Genzyme is ranked third on the global list of 575 companies, the second consecutive year it has achieved this position. Genzyme placed among the...
Market Wire (Free subscription) | 11/26/2009
OTTAWA, ONTARIO (MARKET WIRE) Health Canada is informing health care professionals and Canadians that routine quality control testing has discovered foreign particles in a small number of vials of five products filled at a Genzyme Corporation facility in Boston. Genzyme has also received customer reports of foreign particles in some vials of these products. The particles observed...
PR News Wire (Free subscription) | 11/24/2009
... I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is in Phase...
